What is the Geron Corporation stock price forecast?

Geron Corporation is currently trading at $1.18. View real-time AI analysis on Alpha Lenz.

What is Geron Corporation insider trading activity?

View the latest insider trading data for Geron Corporation on Alpha Lenz.

What is Geron Corporation's P/E ratio?

Geron Corporation's P/E ratio is -9.4.

Geron Corporation

NASDAQ · GERN

$1.18+0.03(+2.61%)Pre-market

Ask about Geron Corporation's future dividend policy...

Alpha Chat Insight

“Geron Corporation trades at a P/E of -9.4 (undervalued) with modest ROE of -33.0%. 3Y revenue CAGR of 575.7% highlights clear growth momentum.”

Ask for details →

Company Overview

Geron Corporation is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics for cancer. The company's primary focus is on imetelstat, a telomerase inhibitor designed to target hematologic myeloid malignancies. By intervening in the process of telomerase activity, which contributes to the unchecked proliferation of cancer cells, Geron aims to advance treatment options that directly address the underlying disease mechanisms. Geron's pursuits are specifically impactful in the fields of hematology and oncology, offering potential breakthroughs in therapeutic solutions for chronic diseases such as myelofibrosis and myelodysplastic syndromes. Based in California, Geron's role in the financial market is underscored by its commitment to extensive clinical trials and its engagement with regulatory pathways to ensure the safety and efficacy of its treatments. The company collaborates with notable academic institutions and industry partners, harnessing cutting-edge research aimed at addressing unmet medical needs in cancer treatment.

CEOMr. Harout Semerjian

Websitehttps://www.geron.com

SectorHealthcare

IndustryBiotechnology

Employees229

Company Statistics

FY 2025

Profile

$786.66MMarket Cap

$183.88MRevenue

0.00Shares Out

229Employees

Margins

97.42%Gross

-17.73%EBITDA

-28.04%Operating

-45.41%Pre-Tax

-45.41%Net

Valuation

-9.42P/E

3.48P/B

4.28EV/Sales

-25.49EV/EBITDA

-7.08P/FCF

Growth (CAGR)

575.72%Rev 3Yr

273.49%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-14.34%ROA

-32.99%ROE

-8.73%ROIC

Financial Health

$77.56MCash & Cash Equivalents

$267.11MNet Debt

152.59%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Geron Corporation trades at a P/E of -9.4 (undervalued) with modest ROE of -33.0%. 3Y revenue CAGR of 575.7% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Geron Corporation (ticker: GERN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 229 employees. Market cap is $787M.

The current price is $1.18 with a P/E ratio of -9.42x and P/B of 3.48x.

ROE is -32.99% and operating margin is -28.04%. Annual revenue is $184M.